Karen S Aboody Selected Research

Enzymes

1/2020	Developing Implantable Scaffolds to Enhance Neural Stem Cell Therapy for Post-Operative Glioblastoma.
1/2019	Quantitative Evaluation of Intraventricular Delivery of Therapeutic Neural Stem Cells to Orthotopic Glioma.
1/2018	Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival.
1/2017	Human Neural Stem Cell Biodistribution and Predicted Tumor Coverage by a Diffusible Therapeutic in a Mouse Glioma Model.
1/2017	Cell-mediated enzyme prodrug cancer therapies.
12/2013	Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
5/2013	Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies.
2/2012	Human neural stem cell tropism to metastatic breast cancer.
9/2010	Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme.
1/2007	Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karen S Aboody Research Topics

Disease

60	Neoplasms (Cancer) 03/2022 - 05/2003
27	Glioma (Gliomas) 03/2022 - 09/2006
13	Brain Neoplasms (Brain Tumor) 01/2020 - 05/2003
8	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2017
8	Neuroblastoma 03/2017 - 12/2006
7	Neoplasm Metastasis (Metastasis) 12/2020 - 01/2009
6	Breast Neoplasms (Breast Cancer) 01/2021 - 12/2009
6	Glioblastoma (Glioblastoma Multiforme) 01/2020 - 09/2013
3	Melanoma (Melanoma, Malignant) 01/2021 - 09/2007
2	Carcinogenesis 12/2016 - 05/2013
2	Disease Progression 01/2009 - 01/2007
1	Bites and Stings (Sting) 01/2021
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Residual Neoplasm 01/2020
1	Ascites 03/2019
1	Inflammation (Inflammations) 04/2015
1	Triple Negative Breast Neoplasms 12/2014
1	Carcinoma (Carcinomatosis) 08/2012

Drug/Important Bio-Agent (IBA)

17	Pharmaceutical PreparationsIBA 03/2022 - 01/2007
16	ProdrugsIBA 01/2020 - 05/2003
13	EnzymesIBA 01/2020 - 05/2003
7	Cytosine DeaminaseIBA 01/2021 - 12/2003
7	Flucytosine (Ancobon)FDA Link 01/2021 - 12/2003
6	AntibodiesIBA 01/2021 - 12/2008
6	Irinotecan (Camptosar)FDA LinkGeneric 03/2017 - 12/2006
5	CytokinesIBA 04/2015 - 05/2003
4	Silicon Dioxide (Silica)FDA LinkGeneric 01/2021 - 01/2017
4	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 05/2013
4	Proteins (Proteins, Gene)FDA Link 03/2019 - 06/2005
4	Carboxylesterase (Hydrolase S)IBA 03/2017 - 01/2007
4	Conditioned Culture MediaIBA 02/2012 - 06/2008
3	GoldIBA 01/2021 - 07/2013
3	Cisplatin (Platino)FDA LinkGeneric 09/2020 - 01/2019
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014 - 06/2005
3	Chemotactic FactorsIBA 01/2014 - 09/2010
3	Interferon-betaIBA 01/2014 - 01/2007
3	Interleukin-8 (Interleukin 8)IBA 08/2012 - 06/2008
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2008 - 06/2005
2	OligonucleotidesIBA 03/2022 - 01/2019
2	Polystyrenes (Polystyrene)IBA 01/2021 - 01/2020
2	Antineoplastic Agents (Antineoplastics)IBA 12/2020 - 09/2011
2	Thymidine KinaseIBA 09/2020 - 01/2020
2	SurvivinIBA 03/2019 - 01/2016
2	Neutralizing AntibodiesIBA 03/2019 - 08/2012
2	Glutathione (Reduced Glutathione)IBA 01/2017 - 12/2016
2	Temozolomide (Temodar)FDA LinkGeneric 12/2016 - 09/2013
2	Trastuzumab (Herceptin)FDA Link 10/2015 - 12/2009
2	Interleukin-6 (Interleukin 6)IBA 02/2012 - 09/2010
2	Monoclonal AntibodiesIBA 11/2010 - 12/2009
2	LuciferasesIBA 01/2009 - 11/2008
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 12/2008 - 06/2008
2	Urokinase Plasminogen Activator ReceptorsIBA 12/2008 - 06/2008
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 03/2022
1	Antisense OligonucleotidesIBA 03/2022
1	Liposomes (Liposome)IBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	resiquimodIBA 01/2021
1	antiglomerular basement membrane antibodyIBA 01/2021
1	Ganciclovir (Cytovene)FDA LinkGeneric 01/2020
1	Polylactic Acid-Polyglycolic Acid CopolymerIBA 01/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	compound 21IBA 06/2017
1	AntioxidantsIBA 01/2017
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017
1	Cystine (L-Cystine)IBA 12/2016
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 12/2016
1	human ERBB2 proteinIBA 10/2015
1	GalactosidasesIBA 04/2015
1	RNA (Ribonucleic Acid)IBA 04/2015
1	SuspensionsIBA 02/2014
1	Stem Cell FactorIBA 01/2014
1	TNF-Related Apoptosis-Inducing LigandIBA 01/2014
1	DNA (Deoxyribonucleic Acid)IBA 01/2014
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2014
1	Oxyquinoline (8 Hydroxyquinoline)FDA Link 01/2014
1	Carboxylic Ester HydrolasesIBA 12/2013
1	Ferrosoferric Oxide (Magnetite)FDA Link 10/2013
1	Dexamethasone (Maxidex)FDA LinkGeneric 05/2013
1	Matrix Metalloproteinases (MMPs)IBA 08/2012
1	Basic Helix-Loop-Helix Transcription FactorsIBA 08/2012
1	Topoisomerase I InhibitorsIBA 02/2012
1	CXCR4 Receptors (CXCR4 Receptor)IBA 01/2012
1	Peptides (Polypeptides)IBA 01/2012
1	HydrogelsIBA 01/2012
1	RADA16-IIBA 01/2012
1	fluorescent protein 583IBA 01/2012
1	NestinIBA 01/2012
1	EsterasesIBA 12/2011

Therapy/Procedure

40	Therapeutics 03/2022 - 05/2003
11	Drug Therapy (Chemotherapy) 12/2021 - 02/2007
4	Injections 03/2022 - 01/2007
4	Oncolytic Virotherapy 12/2020 - 01/2016
4	Radiotherapy 10/2018 - 09/2010
3	Immunotherapy 01/2021 - 12/2009
2	Photothermal Therapy 01/2021 - 12/2014
2	Transplantation 10/2013 - 06/2005
1	Lasers (Laser) 01/2021
1	Biological Therapy 01/2016
1	Intravenous Injections 10/2013